Abstracts

ISOLATION OF PAN-SARBECOVIRUS mABs THAT NEUTRALIZE SARS-CoV-1 AND SARS-CoV-2 VARIANTS

Background: The continued emergence of severe acute respiratory syndrome coronaviruses (SARS-CoVs) and recent explosion of the SARS-CoV-2 pandemic highlights the need for broad and potent antibody recognition and understanding the contexts in which they may develop. Antibodies with cross reactivity across SARS lineages may be of particular value in preparing for future outbreaks of new…

PRIOR SARS-CoV-2 INFECTION PROTECTS AGAINST SYMPTOMATIC COMMON COLD CORONAVIRUSES

Background: Current COVID-19 vaccines provide substantial protection against severe COVID-19, but they do not completely eliminate subsequent SARS-CoV-2 infections. We examined incidence of and immune differences against related but different common cold coronaviruses (ccCoV) as a proxy for response against a future emerging CoV among those with SARS-CoV-2 infection, COVID-19 vaccination, or neither exposure. Methods:…

PERFORMANCE OF URINE XPERT ULTRA VS ALERE LAM FOR DIAGNOSING TB IN HIV IN-PATIENTS

Background: Rapid urine-based TB diagnostics, including lateral flow urinary lipoarabinomannan (LF-LAM), reduce mortality in HIV-positive in-patients. Xpert MTB/RIF Ultra (Ultra) has improved sensitivity on sputum, and may be a useful urine-based diagnostic test for disseminated TB. Methods: We conducted a cross-sectional diagnostic accuracy study at two hospitals in East London, South Africa. From August 2018…

HIGH MORTALITY IN AFRICAN INFANTS HOSPITALIZED WITH SEVERE PNEUMONIA AND ADVANCED HIV

Background: Children with advanced HIV disease are known to have increased risk of mortality, but inpatient and post-discharge death rates for infants hospitalized with severe pneumonia are not well-described. Methods: EMPIRICAL is an ongoing clinical trial (#NCT03915366) supported by EDCTP2 and the European Union (RIA2017MC-2013) enrolling infants 28-365 days age with HIV and severe pneumonia…

DORAVIRINE: SAFETY, TOLERABILITY & EFFICACY IN SOUTH AFRICAN WOMEN ON CONTRACEPTION

Background: Prior to local scale-up of new antiretroviral therapy (ART) for HIV treatment, exploring drug-drug interactions between ART and contraception is crucial. We are conducting EPIC (Evaluation of Pharmacokinetic drug-drug Interactions between Contraceptives and doravirine-containing ART), a parallel group pharmacokinetic study to examine interactions with doravirine (DOR)-containing ART (DOR+3TC+TDF) among women of reproductive potential living…

BEAT2: PEG-IFN-ALPHA + 3BNC117 & 10-1074 REBOUND VIRUS PHENOTYPE AND EVOLUTION

Background: BEAT2 (NCT03588715) tested combined peg-IFN-α2b with two broadly neutralizing antibodies (bnAbs) (3BNC117 and 10-1074) at antiretroviral treatment interruption (ATI) in 14 people living with HIV. Entry criteria included bnAb sensitivity by PhenoSense HIV mAb Assay (IC90 < 2.0 µg/mL (3BNC117) and < 1.5 µg/mL (10-1074)). Primary clinical outcomes are presented elsewhere; here, we report…